RUELLA, MARCO
RUELLA, MARCO
Dip. MEDICINA ED ONCOLOGIA SPERIMENTALE (attivo dal 01/01/1900 al 30/04/2013)
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study
2016-01-01 Ruella, Marco; Filippi, Andrea Riccardo; Bruna, Riccardo; Di Russo, Anna; Magni, Michele; Caracciolo, Daniele; Passera, Roberto; Matteucci, Paola; Di Nicola, Massimo; Corradini, Paolo; Parvis, Guido; Gini, Guido; Olivieri, Attilio; Ladetto, Marco; Ricardi, Umberto; Tarella, Corrado; Devizzi, Liliana
Haploidentical cellular therapy in elderly patients with acute myeloid leukemia: description of its use in high risk patients.
2013-01-01 Cignetti A; Ruella M; Elia A; Tassi V; Redoglia V; Gottardi D; Tarella C.
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose
2013-01-01 130. Devizzi L; Guidetti A; Seregni E; Passera R; Maccauro M; Magni M; Testi A; Di Nicola M; Tarella C; Matteucci P; Viviani S; Ruella M; Carlo-Stella C; Chiesa C; Cox MC; Bombardieri E; Gianni AM.
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia
2011-01-01 Guidetti A; Carlo-Stella C; Ruella M; Miceli R; Devizzi L; Locatelli SL; Giacomini A; Testi A; Buttiglieri S; Risso A; Mariani L; Di Nicola M; Passera R; Tarella C; Gianni AM
The aging effect of chemotherapy on cultured human mesenchymal stem cells
2011-01-01 Buttiglieri S; Ruella M; Risso A; Spatola T; Silengo L; Avvedimento EV; Tarella C
Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
2012-01-01 Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study | 2016 | Ruella, Marco; Filippi, Andrea Riccardo; Bruna, Riccardo; Di Russo, Anna; Magni, Michele; Caracciolo, Daniele; Passera, Roberto; Matteucci, Paola; Di Nicola, Massimo; Corradini, Paolo; Parvis, Guido; Gini, Guido; Olivieri, Attilio; Ladetto, Marco; Ricardi, Umberto; Tarella, Corrado; Devizzi, Liliana | |
| Haploidentical cellular therapy in elderly patients with acute myeloid leukemia: description of its use in high risk patients. | 2013 | Cignetti A; Ruella M; Elia A; Tassi V; Redoglia V; Gottardi D; Tarella C. | |
| Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose | 2013 | 130. Devizzi L; Guidetti A; Seregni E; Passera R; Maccauro M; Magni M; Testi A; Di Nicola M; Tarella C; Matteucci P; Viviani S; Ruella M; Carlo-Stella C; Chiesa C; Cox MC; Bombardieri E; Gianni AM. | |
| Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia | 2011 | Guidetti A; Carlo-Stella C; Ruella M; Miceli R; Devizzi L; Locatelli SL; Giacomini A; Testi A; Buttiglieri S; Risso A; Mariani L; Di Nicola M; Passera R; Tarella C; Gianni AM | |
| The aging effect of chemotherapy on cultured human mesenchymal stem cells | 2011 | Buttiglieri S; Ruella M; Risso A; Spatola T; Silengo L; Avvedimento EV; Tarella C | |
| Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. | 2012 | Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C. |